inno.N

May 17, 2023
 

HK inno.N presents latest research results of K-CAB to gastroenterologists worldwide  

HK inno.N presented new clinical study results of K-CAB, a P-CAB drug for gastroesophageal reflux disease, at an academic seminar attended by 20,000 gastroenterologists from around the world. Three research results including the clinical study for the healing rate of short-term drug administration in erosive reflux disease patients were released through oral and poster presentation. 

HK inno.N announced on the 17th that they presented the newest research results for K-CAB(ingredient name: Tegoprazan) for gastroesophageal reflux disease to domestic and international scholars at Digestive Disease Week 2023(DDW 2023), held recently in Chicago, USA. 

HK inno.N released three research results: ▲A multicenter phase 4 study examining the cure rate of 2 weeks/4 weeks of K-CAB(Tegoprazan) administration in erosive reflux disease(ERD) patients, ▲An investigator initiated study investigating the effects of K-CAB in iatrogenic ulcer patients after endoscopic submucosal dissection(ESD) ▲An investigator initiated study examining changes in gastric emptying after K-CAB administration. 

The study on the healing rate of 2 weeks/4 weeks of K-CAB Tab.(Tegoprazan) administration in erosive reflux disease(ERD) patients was led by Professor Suckchei Choi from the Department of Gastroenterology at Wonkwang University Hospital and presented by Professor Cheolmin Shin from the Department of Gastroenterology at Seoul National University Bundang Hospital. 

The cure rate of administering K-CAB 50 mg(Tegoprazan) for 2 weeks and 4 weeks proved K-CAB’s non-inferiority compared to the PPI treatment group, which served as the control group. In addition, unlike PPIs, which showed different cure rates based on the severity of esophagitis or CYP2C19 genotype, K-CAB showed a stable healing rate regardless of the severity of esophagitis (LA grade C/D) and CYP2C19 genotype. 

The event was crowded with investigators and gastroenterologists from around the world who displayed great interest in K-CAB, engaging in lively Q&A sessions and sharing their opinions.

The study on the “effects of K-CAB for iatrogenic ulcer patients after endoscopic submucosal dissection(ESD),” led by Professor Jongjae Park from the Department of Gastroenterology at Korea University Guro Hospital, was presented by a poster presentation by Professor Byungwook Kim from the Department of Gastroenterology at the Catholic University of Korea Incheon St. Mary's Hospital. The study result was presented at KDDW held in Korea last year and again at DDW this year to global investigators. 

As a result, K-CAB proved non-interiority in the healing of iatrogenic ulcer compared to esomeprazole, a PPI and showed a higher healing rate (30.3% vs 22.1%)at the 4-week mark.

Endoscopic submucosal dissection(ESD) is an endoscopic healing method for gastric adenoma or early gastric cancer, and the ulcer derived from it is called an “iatrogenic ulcer.” A swift gastric acid inhibition after endoscopic submucosal dissection is essential for the prompt healing of ulcers while preventing bleeding and perforation. Through this study, HK inno.N was able to acquire clinical data that shows the healing effect of K-CAB for ulcers.

The results of the “study on changes in gastric emptying related to the administration of K-CAB,” led by Professor Hyekyung Jung from the Department of Gastroenterology at Ewha Womans University Mokdong Hospital, was also presented.

According to Professor Cheong, PPIs has its limitations in that it delays gastric emptying during the normal eating process as it affects the digesting process. On the other hand, K-CAB which belongs to the P-CAB category, did not significantly impact gastric emptying during meals in healthy adults or dyspepsia such as fullness after eating or early satiety.

CEO Dalwon Kwak from HK inno.N. stated, “K-CAB is the leading product that has created the P-CAB market in South Korea, and we have consistently been presenting the latest research results at major academic conferences worldwide, such as Digestive Disease Week(DDW) and the United European Gastroenterology Week(UEGW).” He further added, “We are conducting various differentiated studies to enhance the competitiveness of K-CAB not only in the domestic market but also in the global market. Through continuous clinical studies and publication of papers, we will widely promote the value of K-CAB.”

Image 2. HK inno.N’s K-CAB Product Photo 

HK inno.N’s K-CAB(ingredient name: Tegoprazan) is a P-CAB category used for the treatment of gastroesophageal reflux disease. It has the most indications among the same class of drugs in South Korea, including ▲erosive reflux disease ▲non-erosive reflux disease ▲gastric ulcer ▲antibiotic combination to eradicate helicobacter pylori ▲maintenance therapy after treatment of erosive reflux disease. It has been launched in two formulations, IR tablets(25 mg and 50 mg) and orally disintegrating tablets(50 mg), and has recorded annual sales of 132.1 billion KRW in the past year through outpatient prescriptions. K-CAB has been approved in 35 countries including the USA and China and has completed its launch in China, Philippines, Mexico and Mongolia.

Reference 

- Research Titles

▶Oral presentation - Comparison of Tegoprazan and Lansoprazole in Patients with Erosive Esophagitis: A Multicenter, Randomized, Double-Blind, Active-Comparator Phase 4 Trial 

▶Poster - The Effect of Tegoprazan for Treating Endoscopic Submucosal Dissection-Induced Artificial Ulcer; A Multicenter, Randomized, Active-Controlled Study

▶Poster - Effects of Tegoprazan, Potassium Competitive Acid Blocker, on Gastric Emptying: A Pilot Study

- Terminologies

▶PPI (Proton Pump Inhibitor)

▶P-CAB (Potassium Competitive Acid Blocker)

▶ESD (Endoscopic Submucosal Dissection)

▶ERD (Erosive Reflux Disease)